|Bid||0.00 x 900|
|Ask||0.00 x 47300|
|Day's Range||134.97 - 135.00|
|52 Week Range||116.77 - 163.94|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||44.17|
|Earnings Date||Jan 30, 2019 - Feb 4, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||140.24|
athenahealth Inc NASDAQ/NGS:ATHNView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low and declining * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for ATHN with fewer than 5% of shares on loan. Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on February 1. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding ATHN totaled $1.26 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Athenahealth (ATHN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The latest launch reflects Integra LifeSciences' (IART) consistent efforts to boost the Orthopedics and Tissue Technologies segment.
NEW YORK, Jan. 11, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Boston Scientific's (BSX) solid top line is expected to be backed by growth across all segments and geographical regions in Q4.
QIAGEN (QGEN) pins high hopes on its strategic tie-ups with Hamilton and DiaSorin. It unveils a CE-marked DiaSorin automation solution in Europe to use the LIAISON system for test read-out.
Hologic's (HOLX) strong top line is primarily expected on the back of balanced growth across a majority of the company's segments in Q1.
NEW YORK, Jan. 07, 2019 -- The following statement is being issued by Levi & Korsinsky, LLP: Levi & Korsinsky, LLP announces that investigations have commenced on.
Cardiovascular Systems (CSII) continues to expand its portfolio to widen the company's reach. However, Cardiovascular Systems operating in a highly competitive environment is a concern.
Within Covance Drug Development business, LabCorp (LH) aims at reaping huge profits via expanded solutions and better operational skills.
Cerner's (CERN) ePrescribe workflow solution is likely to partner with CoverMyMeds' RxBenefit Clarity solution for prescription price transparency.
NEW YORK , Dec. 28, 2018 /PRNewswire/ -- Aphria Inc. (APHA) Lifshitz & Miller announces investigation into possible securities laws violations in connection with a report alleging that Aphria is part ...
NEW YORK, NY / ACCESSWIRE / December 21, 2018 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the EmpireState Building in New ...